Evogene (EVGN) Amortizatization of Intangibles (2019 - 2025)
Evogene (EVGN) posted Amortizatization of Intangibles of $240000.0 for Q1 2025, down 2.04% sequentially from $245000.0 in Q4 2024, and down 2.04% YoY from $245000.0 in Q1 2024.
Evogene (EVGN) Amortizatization of Intangibles (2019 - 2025) Analysis & Trends
Evogene has reported Amortizatization of Intangibles for 7 years, with the latest figure at $240000.0 in Q1 2025.
- Quarterly Amortizatization of Intangibles fell 2.04% year-over-year to $240000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $969000.0 (down 0.72% YoY) and the FY2024 annual result came in at $974000.0, changed 0.31% from the prior year.
- Amortizatization of Intangibles fell to $240000.0 in Q1 2025 per EVGN's latest filing, from $245000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $335000.0 in Q1 2022 and troughed at $230000.0 in Q1 2021.
- A 5-year average of $246117.6 and a median of $242000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles soared 45.65% in 2022, then decreased 28.36% in 2023.
- Over 5 years, Amortizatization of Intangibles stood at $235000.0 in 2021, then rose by 4.26% to $245000.0 in 2022, then changed by 0.0% to $245000.0 in 2023, then changed by 0.0% to $245000.0 in 2024, then fell by 2.04% to $240000.0 in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $240000.0, $245000.0, and $245000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 240,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Dec 31, 2024 | 245,000.00 |
| Dec 31, 2024 | 245,000.00 |
| Sep 30, 2024 | 245,000.00 |
| Sep 30, 2024 | 245,000.00 |
| Jun 30, 2024 | 239,000.00 |
| Jun 30, 2024 | 239,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 245,000.00 |
| Dec 31, 2023 | 245,000.00 |
| Sep 30, 2023 | 245,000.00 |
| Sep 30, 2023 | 245,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Mar 31, 2023 | 240,000.00 |
| Mar 31, 2023 | 240,000.00 |
| Dec 31, 2022 | 245,000.00 |
| Dec 31, 2022 | 245,000.00 |